Saniona AB (SE:SANION)
:SANION
Want to see SE:SANION full AI Analyst Report?
SANION Stock Chart & Stats
kr21.10
-kr0.15(-2.06%)
At close: 4:00 PM EST
kr21.10
-kr0.15(-2.06%)
Day’s Range― - ―
52-Week Rangekr7.05 - kr28.30
Previous CloseN/A
Volume191.43K
Average Volume (3M)1.06M
Market Cap
kr1.94B
Enterprise Valuekr1.36B
Total Cash (Recent Filing)kr580.82M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)9.6
Beta-0.18
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding138,030,140
10 Day Avg. Volume913,988
30 Day Avg. Volume1,064,614
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthReporting zero total debt in 2025 and a stronger equity base materially reduces refinancing and interest-rate risk. This durable improvement increases financial optionality to fund R&D, pursue partnerships or license deals without immediate capital raises, supporting multi-month program continuity.
Cash Generation RecoveryPositive operating and free cash flow across two consecutive years signals a structural shift from prior cash burn. Sustained cash generation enhances runway for clinical programs, reduces dilution risk from frequent financing, and enables the company to self-fund key activities over the coming months.
Profitability TurnaroundReturning to net income with strong 2024–2025 margins indicates the business can achieve profitable operations when revenue holds. Durable profitability improves management flexibility, supports reinvestment in the pipeline, and makes Saniona a more credible partner for licensing and collaboration.
Bears Say
Revenue And Cashflow VolatilityLarge swings in revenue and a 64.8% FCF decline in 2025 show core cash and sales are volatile. Such variability makes multi-month planning harder, raises the likelihood of near-term financing needs, and puts program timelines and R&D funding at risk absent stabilised top-line performance.
Historical Capital-structure InstabilityAlthough 2025 shows no debt, the recent history of negative equity and past higher leverage signals prior dependence on external funding. That track record increases the chance management may need to re-lever or dilute shareholders if setbacks recur, a structural governance and funding risk.
Small Scale And Early-stage Pipeline RiskA 22-person organization focused on preclinical/clinical small-molecule programs faces constrained internal bandwidth for development and commercialization. Long timelines and binary clinical outcomes amplify execution risk, making durable progress heavily reliant on partnerships and consistent funding.
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was kr7.05 and its highest was kr28.30 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr1.94B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is May 27, 2026 which is in 26 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on Feb 26, 2026. The company reported -kr0.302 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.302.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.302 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.498%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in SE:SANION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---